-
2024-514419-93-00
9
2022-05-19
Study to investigate the safety and efficacy of GB1211 (a galectin-3 i
-
2023-504363-17-00
7
2022-05-13
Advanced MTAP-null solid tumors
-
2024-511996-13-00
5
2022-05-11
Previously untreated, unresectable, or metastatic melanoma
-
2022-502802-34-00
5
2022-04-05
Dravet and Lennox-Gastaut Syndromes
-
2024-510696-38-00
5
2022-03-08
Severe Hypertriglyceridemia.
-
2023-506511-17-00
4
2022-03-07
Binge eating disorder
-
2023-503572-24-00
5
2022-03-02
Chronic Obstructive Pulmonary Disease (COPD)
-
2024-516021-32-00
5
2022-02-17
Critically ill patients suffering from CIRCI
-
2024-515039-31-00
4
2022-02-10
Isatuximab in type I cryoglobulinaemia: A prospective pilot study
-
2023-506589-30-00
5
2022-02-09
Invasive Extraintestinal Pathogenic Escherichia coli Disease
-
2023-507688-20-00
5
2021-12-03
Participants with completely resected Stage III or Stage IV melanoma
-
2024-512945-18-00
5
2021-11-30
Geographic Atrophy Secondary to Age-Related Macular Degeneration
-
2022-501615-14-00
4
2021-11-08
Classical Hodgkin Lymphoma
-
2024-515102-12-00
4
2021-11-02
Advanced Cancer Whose Tumours Contain Molecular Alterations
-
2023-510057-41-00
5
2021-10-06
Patients With Homozygous and Heterozygous Familial Hypercholesterolemi
-
2024-510744-31-00
5
2021-10-06
Giant cell arteritis (GCA)
-
2023-505284-36-00
4
2021-09-13
Advanced solid tumors
-
2024-512622-29-00
7
2021-09-10
Cholangiocarcinoma (CCA) and Other Advanced Solid Tumors
-
2024-512880-30-00
5
2021-08-27
Neovascular Age-related Macular Degeneration (wet AMD)
-
2024-511158-36-00
9
2021-08-05
Metastatic colorectal cancer
-
2024-512227-36-00
9
2021-07-28
Advanced solid tumors
-
2024-513870-23-00
5
2021-06-28
Locally Advanced or Metastatic Unresectable Urothelial Cancer
-
2024-513672-17-00
4
2021-06-14
Inoperable Chronic thromboembolic pulmonary hyperTension
-
2022-500385-99-00
5
2021-06-03
SARS-CoV II infection (Coronavirus disease)